ABSTRACT
We report the development of a Weibull based Long-Short-Term-Memory approach (W-LSTM) for the prediction of COVID-19 disease. The W-LSTM model developed in this study, performs better in terms of MSE, R2 and MAPE, as compared to the previously published models, including ARIMA, LSTM and their variations. Using W-LSTM model, we have predicted the beginning and end of the current cycle of COVID-19 in several countries. Performance of the model was validated as satisfactory in 82% of the 50 test countries, while asking for prediction for 10 days beyond the period of training. Accuracy of the above prediction with days beyond training was assessed in comparison with the MAPE that the model gave with cumulative global data. The model was applied to study correlation between the growth of infection and deaths, and a number of effectors that may influence the epidemic. The model identified age groups, trade with China, air traffic, country temperature and CoV-2 virus types as the likely effectors of infection and virulence leading to deaths. The predictors likely to promote or suppress the epidemic were identified. Some of the predictors had significant effect on the shape parameters of Weibull distribution. The model can function on cloud, take inputs in real time and handle large data country wise, at low costs to make predictions dynamically. Such predictions are highly valuable in guiding policy makers, administration and health. Interactive curves generated from the W-LSTM model can be seen at http://collaboration.coraltele.com/covid2/.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
R. Tuli acknowledges the grant provided by Science & Engineering Research Board, Department of Science & Technology, Government of India towards the JC Bose National Fellowship. Authors acknowledge Coral Telecom Ltd., Noida, India for hosting the model on their server.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
1 Email: shreshthtuli{at}gmail.com, shikhartuli{at}gmail.com, ruchituli{at}gmail.com, rakeshtuli{at}hotmail.com
Data Availability
Our prediction model is available online at https://github.com/shreshthtuli/covid-19-prediction. Few interactive graphs can be seen at https://collaboration.coraltele.com/covid2/.
https://github.com/shreshthtuli/covid-19-prediction
https://ourworldindata.org/coronavirus
https://wits.worldbank.org/CountryProfile/en/Country/CHN/Year/2018/
https://www.indexmundi.com/facts/indicators/SH.MLR.TRET.ZS
https://www.biorxiv.org/content/10.1101/2020.05.04.075911v1.supplementary-material
Abbreviations
- ML
- Machine Learning
- SARS-CoV-2
- Severe Acute Respiratory Syndrome Coronavirus 2
- COVID-19
- Coronavirus disease